Eledon Pharmaceuticals Q3 net loss narrows on warrant gain
Overview
US biotech firm's Q3 net loss narrowed yr/yr, aided by non-cash warrant liability gain
Operating expenses for Q3 rose yr/yr to $21.7 mln
Company received FDA Fast Track for tegoprubart in kidney transplantation, IND clearance for islet cell trial
Outlook
Company plans to initiate global Phase 3 LEGACY trial in kidney transplantation in Q4 2026
Eledon expects to start registrational study of tegoprubart in islet cell transplantation
Company anticipates cash runway into Q2 2027
Result Drivers
CLINICAL PROGRAM PROGRESS - Increased R&D expenses attributed to advancing tegoprubart clinical trials in kidney and islet cell transplantation
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $3.93 mln | ||
Q3 Income from Operations | -$21.67 mln | ||
Q3 Operating Expenses | $21.67 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $8.00, about 199.6% above its November 11 closing price of $2.67
Reuters Recommended Reads
Nov 12 - Equillium posts narrower-than-expected Q3 net loss; expects cash runway to fund operations into 2029
Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall
Nov 12 - Prime Medicine Q3 loss narrows as expenses decline
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)